Celltrion (068270) investor relations material

Executive summary

• Achieved record-high quarterly revenue and profitability in 2Q26, with Young Products driving accelerated growth and Advanced Products maintaining stable performance.

• Consolidated H1 2026 revenue was KRW 2,538.7 billion and operating income KRW 773.7 billion, reflecting continued growth from biopharmaceuticals and expanded global sales channels.

• Major M&A activities, including the acquisition of GIFRER BARBEZAT and integration of Celltrion Healthcare, strengthened global distribution and manufacturing.

• Maintained robust financial position with total assets of KRW 23.7 trillion and equity of KRW 18.0 trillion as of June 2026.

Financial highlights

• Total sales reached KRW 1,393.7 billion in 2Q26, up 45.0% YoY and 21.7% QoQ; H1 2026 revenue was KRW 2,538.7 billion.

• Operating profit was KRW 451.8 billion in 2Q26, up 86.3% YoY; H1 2026 operating income was KRW 773.7 billion.

• Net profit for 2Q26 was KRW 371 billion, up 320.2% YoY; H1 2026 net income was KRW 721.2 billion.

• Gross profit margin rose to 62.0% in 2Q26; H1 2026 gross margin was 61.1%.

• Young Products sales grew 72.5% YoY to KRW 825 billion; five newly launched products contributed over KRW 300 billion in combined sales.

Outlook and guidance

• Annual revenue is projected to outperform initial guidance, supported by rapid market penetration of Young Products.

• Management targets FY2026 revenue of KRW 5.3 trillion, with quarterly operating income goals rising from KRW 3,000 billion in Q1 to KRW 6,000 billion in Q4.

• Growth momentum anticipated to accelerate in 2H26 through regional expansion, new product launches, and CDMO business focus.